Tissue fibrosis inhibitor in which biocompatible polymer is used

Abstract

A problem to be solved by the present invention is to provide a fibrosis inhibitor that solves the problem of inhibiting fibrosis of an organ or tissue surface, and especially of inhibiting fibrosis of an epicardial surface. Furthermore, by inhibiting fibrosis, the present invention prevents or reduces subsequent development of adhesions to avoid organ or tissue damage during re-operation. Provided is a fibrosis inhibitor for inhibiting fibrosis of a tissue by fixing a biocompatible polymer to a tissue where it is desirable to inhibit fibrosis.

1 . A tissue fibrosis inhibitor comprising a biocompatible polymer. 
     
     
         2 . The fibrosis inhibitor according to  claim 1 , wherein the biocompatible polymer is fibrin or a dextrin gel. 
     
     
         3 . A tissue fibrosis inhibition kit comprising a combination of a biocompatible polymer and a cell scaffold material. 
     
     
         4 . The fibrosis inhibition kit according to  claim 3 , wherein the biocompatible polymer is fixed to one tissue fibrosis of which is to be inhibited, and prosthesis is made with the cell scaffold material for a tissue defect site in the other tissue. 
     
     
         5 . The fibrosis inhibition kit according to  claim 3 , wherein the biocompatible polymer is fibrin or a dextrin gel. 
     
     
         6 . The fibrosis inhibition kit according to  claim 3 , wherein the cell scaffold material is a decellularized tissue. 
     
     
         7 . The fibrosis inhibition kit according to  claim 6 , wherein the decellularized tissue is a tissue produced by decellularizing a biological tissue selected from the group consisting of a small intestinal submucosa, pericardium, bladder, amnion, dura mater, peritoneum, greater omentum, thoracic diaphragm, fascia, dermis and skin. 
     
     
         8 . The fibrosis inhibition kit according to  claim 3 , which promotes the self-organization of the cell scaffold material. 
     
     
         9 . The fibrosis inhibition kit according to  claim 3 , wherein the tissue fibrosis of which is to be inhibited is epicardium. 
     
     
         10 . A tissue fibrosis inhibition kit comprising a combination of a biocompatible polymer and a pericardial substitute. 
     
     
         11 . The fibrosis inhibition kit according to  claim 10 , wherein the biocompatible polymer is fixed to one tissue fibrosis of which is to be inhibited, and prosthesis is made with the pericardial substitute for a tissue defect site in the other tissue. 
     
     
         12 . The fibrosis inhibition kit according to  claim 10 , wherein the biocompatible polymer is fibrin or a dextrin gel. 
     
     
         13 . The fibrosis inhibition kit according to  claim 10 , wherein the pericardial substitute is a decellularized tissue. 
     
     
         14 . The fibrosis inhibition kit according to  claim 13 , wherein the decellularized tissue is a tissue produced by decellularizing a biological tissue selected from the group consisting of a small intestinal submucosa, pericardium, bladder, amnion, dura mater, peritoneum, greater omentum, thoracic diaphragm, fascia, dermis and skin. 
     
     
         15 . The fibrosis inhibition kit according to  claim 10 , which promotes the self-organization of the pericardial substitute. 
     
     
         16 . The fibrosis inhibition kit according to  claim 10 , wherein the tissue fibrosis of which is to be inhibited is pericardium. 
     
     
         17 . An adhesion barrier kit, wherein the biocompatible polymer is fixed to one tissue fibrosis of which is to be inhibited, and prosthesis is made with the cell scaffold material or the pericardial substitute for a tissue defect site in the other tissue. 
     
     
         18 . The adhesion barrier kit according to  claim 17 , wherein the biocompatible polymer is fibrin or a dextrin gel. 
     
     
         19 . The adhesion barrier kit according to  claim 17 , wherein the cell scaffold material or the pericardial substitute is a decellularized tissue. 
     
     
         20 . The adhesion barrier kit according to  claim 19 , wherein the decellularized tissue is a tissue produced by decellularizing a biological tissue selected from the group consisting of a small intestinal submucosa, pericardium, bladder, amnion, dura mater, peritoneum, greater omentum, thoracic diaphragm, fascia, dermis and skin. 
     
     
         21 . The adhesion barrier kit according to  claim 17 , which promotes the self-organization of the cell scaffold material or the pericardial substitute. 
     
     
         22 . The adhesion barrier kit according to  claim 17 , wherein the tissue to be inhibited from adhesion is epicardium.